Crystalline form of r)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin- 5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate

Abstract

A crystalline form of crystalline (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate, methods of making the crystalline form and pharmaceutical compositions comprising the crystalline form are useful antibiotics. Further, the derivatives of the present invention may exert potent antibacterial activity versus various human and animal pathogens, including Gram-positive bacteria such as Staphylococi, Enterococci and Streptococi, anaerobic microorganisms such as Bacteroides and Clostridia, and acid-resistant microorganisms such as Mycobacterium tuberculosis and Mycobacterium avium . Accordingly, the compositions comprising the crystalline form may be used in antibiotics.

What is claimed is: 
     
         1 . Crystalline particles comprising
 at least about 96% by weight of (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate   wherein the remainder of the crystalline particles comprises at least one compound selected from the group consisting of   
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         2 . The crystalline particles of  claim 1 , wherein the remainder of the crystalline particles comprises at least one compound selected from the group consisting of: 
       
         
           
           
               
               
           
         
       
     
     
         3 . The crystalline particles of  claim 2  comprising at least about 97% by weight of (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen. 
     
     
         4 . The crystalline particles of  claim 2 , wherein the median volume diameter is at least about 1.0 μm. 
     
     
         5 . A pharmaceutical composition comprising the crystalline particles of  claim 1  and at least one pharmaceutically acceptable carrier, excipient or diluent. 
     
     
         6 . A pharmaceutical composition comprising the crystalline particles of  claim 2  and at least one pharmaceutically acceptable carrier, excipient or diluent. 
     
     
         7 . The pharmaceutical composition of  claim 6 , wherein the pharmaceutically acceptable carrier, excipient or diluent is at least one member selected from the group consisting of mannitol, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, and magnesium stearate. 
     
     
         8 . A reaction mixture comprising the crystalline particles of  claim 1  and a base. 
     
     
         9 . A reaction mixture comprising the crystalline particles of  claim 2  and a base. 
     
     
         10 . The reaction mixture of  claim 8 , wherein the base is sodium hydroxide. 
     
     
         11 . The reaction mixture of  claim 9 , wherein the base is sodium hydroxide. 
     
     
         12 . A pharmaceutical composition comprising a lyophilisate of the reaction mixture of  claim 8 , comprising 
       
         
           
           
               
               
           
         
         wherein R═PO(ONa) 2 . 
       
     
     
         13 . A pharmaceutical composition comprising a lyophilisate of the reaction mixture of  claim 9 , comprising 
       
         
           
           
               
               
           
         
         wherein R═PO(ONa) 2 . 
       
     
     
         14 . A pharmaceutical composition comprising a combination of at least about 96% by weight of a compound having the following structure: 
       
         
           
           
               
               
           
         
         wherein R═PO(ONa) 2 ; and 
         wherein the remainder of the combination comprises at least one salt of a compound selected from the group consisting of: 
       
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       and
 at least one pharmaceutically acceptable carrier, excipient or diluent. 
 
     
     
         15 . The pharmaceutical composition of  claim 14 , wherein the combination comprises at least one salt of 
       
         
           
           
               
               
           
         
       
     
     
         16 . The pharmaceutical composition of  claim 14 , wherein the combination comprises at least about 97% by weight of 
       
         
           
           
               
               
           
         
         wherein R═PO(ONa) 2 . 
       
     
     
         17 . The pharmaceutical composition of  claim 15  wherein the combination comprises at least about 97% by weight of 
       
         
           
           
               
               
           
         
         wherein R═PO(ONa) 2 . 
       
     
     
         18 . A method of treating a bacterial infection comprising administering an effective amount of the crystalline particles of  claim 1  to a subject in need thereof. 
     
     
         19 . A method of treating a bacterial infection comprising administering an effective amount of the pharmaceutical composition of  claim 15  to a subject in need thereof. 
     
     
         20 . A process for making the crystalline particles of  claim 1 , comprising drying the crystalline particles. 
     
     
         21 . The process of  claim 20 , further comprising filtering the crystalline particles from a supernatant before the drying step. 
     
     
         22 . The process of  claim 21 , further comprising contacting a salt of crystalline (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate with an acid solution to form crystallized (R)-3-(4-(2-(2-methyl-tetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate before the filtering step. 
     
     
         23 . The process of  claim 22 , wherein the acid solution comprises HCl and ethanol, or HCl and THF.